Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:ATNM
Previous SymbolAMEX:ATNM
CUSIPN/A
Phone+1-646-6773875
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees25
Outstanding Shares114,700,000
Market Cap$0.00
OptionableOptionable
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions
What is Actinium Pharmaceuticals' stock symbol?
Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."
How were Actinium Pharmaceuticals' earnings last quarter?
Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) posted its earnings results on Monday, March, 16th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.19) by $0.02. View Actinium Pharmaceuticals' Earnings History.
When is Actinium Pharmaceuticals' next earnings date?
What price target have analysts set for ATNM?
3 Wall Street analysts have issued 12-month price objectives for Actinium Pharmaceuticals' stock. Their forecasts range from $3.00 to $6.00. On average, they expect Actinium Pharmaceuticals' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 668.9% from the stock's current price. View Analyst Price Targets for Actinium Pharmaceuticals.
What is the consensus analysts' recommendation for Actinium Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Actinium Pharmaceuticals.
What are Wall Street analysts saying about Actinium Pharmaceuticals stock?
Here are some recent quotes from research analysts about Actinium Pharmaceuticals stock:
- 1. Maxim Group analysts commented, "Actinium announced that the Data Monitoring Committee (DMC) unanimously voted to recommend the Phase 3 SIERRA trial of Iomab-B to continue as planned. The interim safety look occurred at the 25% enrollment mark. The company will host a conference call Wednesday/tomorrow at 9am ET." (8/14/2018)
- 2. According to Zacks Investment Research, "Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. " (7/24/2018)
Has Actinium Pharmaceuticals been receiving favorable news coverage?
Media headlines about ATNM stock have been trending somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Actinium Pharmaceuticals earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future.
Are investors shorting Actinium Pharmaceuticals?
Actinium Pharmaceuticals saw a decrease in short interest in October. As of October 31st, there was short interest totalling 3,279,414 shares, a decrease of 18.2% from the October 15th total of 4,007,153 shares. Based on an average daily volume of 1,083,389 shares, the short-interest ratio is currently 3.0 days. Approximately 3.0% of the company's shares are short sold. View Actinium Pharmaceuticals' Current Options Chain.
Who are some of Actinium Pharmaceuticals' key competitors?
Some companies that are related to Actinium Pharmaceuticals include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB), Antibe Therapeutics (ATE) and AorTech International (AOR).
Who are Actinium Pharmaceuticals' key executives?
Actinium Pharmaceuticals' management team includes the folowing people:
- Mr. Sandesh C. Seth, Chairman & CEO (Age 54)
- Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer (Age 32)
- Dr. Mark S. Berger, Chief Medical Officer (Age 63)
- Dr. Nitya G. Ray, Exec. VP and Head of Product Devel., Manufacturing & Supply Chain (Age 65)
- Dr. Dale L. Ludwig, Chief Scientific Officer (Age 56)
Who are Actinium Pharmaceuticals' major shareholders?
Actinium Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Essex Investment Management Co. LLC (1.00%), PNC Financial Services Group Inc. (0.73%) and Virtu Financial LLC (0.17%). Company insiders that own Actinium Pharmaceuticals stock include Ajit Shetty, Nitya G Ray, Sandesh Seth and Steve O'loughlin. View Institutional Ownership Trends for Actinium Pharmaceuticals.
Which institutional investors are buying Actinium Pharmaceuticals stock?
ATNM stock was acquired by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, PNC Financial Services Group Inc. and Virtu Financial LLC. Company insiders that have bought Actinium Pharmaceuticals stock in the last two years include Ajit Shetty, Nitya G Ray, Sandesh Seth and Steve O'loughlin. View Insider Buying and Selling for Actinium Pharmaceuticals.
How do I buy shares of Actinium Pharmaceuticals?
Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Actinium Pharmaceuticals' stock price today?
One share of ATNM stock can currently be purchased for approximately $0.5202.
What is Actinium Pharmaceuticals' official website?
How can I contact Actinium Pharmaceuticals?
Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.
MarketBeat Community Rating for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)
MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe ATNM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days.
